直接口服抗凝剂与肝素治疗与癌症有关的中风:增强的元分析
Muhammed Amir Essibayi1,2, Ahmed Y Azzam2, Ugur Sener3
1Department of Radiology, Mayo Clinic, Rochester, MN, USA.
medRxiv : the preprint server for health sciences
|December 16, 2024
概括
直接口服抗凝剂 (DOAC) 在预防癌症患者复发性中风方面显示出与肝素相似的安全性和有效性. 由于这些抗血栓剂的数据有限,需要进行进一步的研究.
科学领域:
- 神经科学是一个神经科学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺血性中风对全身恶性瘤患者具有重大风险,导致结果比一般人群更差.
- 癌症患者中继性中风预防的最佳策略尚不清楚.
- 这项研究解决了关于抗血栓剂在癌症相关中风中使用证据的需求.
研究的目的:
- 评估直接口服抗凝剂 (DOAC) 与肝素产品对癌症患者中继性中风预防的疗效和安全性.
- 为了比较DOAC和肝素之间的出血并发症和死亡率.
- 探索计算增强在预测试验结果方面的潜力.
主要方法:
- 通过PubMed搜索识别的癌症相关中风抗血栓药物研究的系统审查和元分析.
- 包括7项符合条件的研究,包括439名接受DOAC治疗的患者和3968名接受肝素治疗的患者.
- 计算增强的应用,以增强样本大小和预测治疗效果.
主要成果:
- 接受氨酸治疗的患者的脑内出血率 (8.8%与1.6%相比),整体出血并发症 (17.9%与3.5%相比) 和死亡率 (28.1%与23.5%) 与接受DOAC治疗的患者相比显著增加.
- 在复发性深静脉血栓塞,临床显著的出血或组之间的整体临床结果中没有发现显著差异.
- 增强的元分析也得出了类似的发现,支持了主要的结果.
结论:
- 直接口服抗凝剂 (DOACs) 可能提供与肝素产品相比较的安全性和有效性,用于预防癌症患者中风复发.
- 这些发现表明,DOACs是预防中风的潜在替代方案,在这个脆弱的人群中.
- 由于研究数量有限和样本规模小,对结果的解释应该谨慎.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
608
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:12Hazard Ratio
87
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
87
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
467
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
467
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K